The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases.
Hepatol Forum
; 1(1): 8-13, 2020 Jan.
Article
en En
| MEDLINE
| ID: mdl-35949666
ABSTRACT
Background and Aim:
Noninvasive scores are developed for the estimation of advanced fibrosis, including parameters in addition to transaminases in non-alcoholic fatty liver disease (NAFLD). In this study, we aimed to investigate the diagnostic performances of Fibrosis-4 (FIB-4) and NAFLD Fibrosis Score (NFS) in the estimation of advanced fibrosis comparing patients with normal and elevated transaminases. Material andMethods:
We retrospectively analyzed the prospectively collected data of a total of 407 consecutive patients with biopsy-proven NAFLD. FIB-4 scores of <1.3 and >2.67 or <1.45 and >3.25 indicated a low and high risk for advanced fibrosis, respectively. NFS scores of <-1.455 and >0.676 were used to assess low and high risk for advanced fibrosis, respectiv.Results:
FIB-4 cutoffs of <1.3 and <1.45 for low risk of advanced fibrosis had a sensitivity of 70% and 54% in patients with elevated transaminases and 70% and 52% in patients with normal transaminases, respectively. The specificities for the cutoffs of >2.67 and >3.25 were 97% and 98% in patients with elevated transaminases and 99% and 100% in patients with normal transaminases, respectively. Concerning NFS, we found similar results.Conclusion:
FIB-4 and NFS showed acceptable diagnostic performance in the exclusion of advanced fibrosis in both populations with normal and elevated transaminases.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Aspecto:
Patient_preference
Idioma:
En
Revista:
Hepatol Forum
Año:
2020
Tipo del documento:
Article
País de afiliación:
Alemania